Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06542874 · ClinicalTrials.gov registry record · Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 448
- Enrollment target
NCT06542874 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 448 participants.
The verdict
NCT06542874, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 448 participants
- Enrollment target
Study Summary
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Interventions
- DRUG NNC0487-0111 subcutanous
- DRUG Placebo (NNC0487-0111 subcutanous)
- DRUG NNC0487-0111 oral
- DRUG Placebo (NNC0487-0111 oral)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2025-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06542874
The ClinicalTrials.gov registry entry for NCT06542874 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 448 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which NNC0487-0111 subcutanous is the first listed.
NCT06542874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06542874 about?
NCT06542874 is a clinical study titled "A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes". The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get...
What is the current status of trial NCT06542874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 448 participants. The study started on 2024-08-07. Estimated completion is 2025-10-24.
What interventions are being tested in trial NCT06542874?
The interventions under investigation include: NNC0487-0111 subcutanous (DRUG), Placebo (NNC0487-0111 subcutanous) (DRUG), NNC0487-0111 oral (DRUG), Placebo (NNC0487-0111 oral) (DRUG).
Who is sponsoring clinical trial NCT06542874?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.